# ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors

> **NCT01031212** · PHASE1 · WITHDRAWN · sponsor: **University of California, San Francisco**

## Conditions studied

- Tumors

## Interventions

- **DRUG:** ASA404
- **DRUG:** Cetuximab
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT01031212
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-01
- **Primary completion:** 2012-06
- **Final completion:** 2013-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The investigator has left the institution (UCSF) prior to study start-up
- **Last updated:** 2013-05-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01031212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01031212, "ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01031212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*